HH Kim, CEO and President of MetaVia, asks what the next generation of GLP-1 drugs might look like. Over the past two decades, only a few biotech sectors have experienced a hype cycle as rapid and publicly frenzied as the obesity drug sector. In just over a year, GLP-1s have transformed from a medical oddity into a cultural […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!